Article

Micropulse laser trabeculoplasty seems to reduce IOP associated with OAG

Micropulse laser trabeculoplasty seems to be effective in reducing the IOP that previously could not be controlled medically in eyes with open-angle glaucoma.

Key Points

"The mechanism of action of laser trabeculoplasty is poorly understood," he said, "but the most recent hypotheses point toward a responsive cellular biochemical cascade that could only occur in viable cells activated, but not killed, by a non-lethal thermal insult directly applied, as in the case of MLT, or derived from higher and lethal photothermal elevations produced by the laser in adjacent cells as in the case of argon laser trabeculoplasty." Dr. Fea is the Aggregate Professor, Department of Clinical Physiopathology, ophthalmology section, University of Turin, Turin, Italy.

The study included 32 eyes of 20 consecutive patients with OAG. All patients had IOP that exceeded 22 mm Hg, had not undergone a previous glaucoma surgery or had severe visual field defects, and had been receiving maximal medical therapy.

IOP values were measured preoperatively and at 3 hours, 1 day, 1 week, and 3, 6, 9, and 12 months postoperatively. After laser application, the patients continued with their medical regimens.

The criteria for successful laser treatment were a decrease in IOP of more than 3 mm Hg and an IOP less than 21 mm Hg during the first week after treatment. Treatment failure was defined as an IOP exceeding 21 mm Hg or an IOP decrease of 3 mm Hg or less during follow-up, he said.

"The mean IOP of 24.7 mm Hg had a prompt and significant decrease [p <0.01] that was maintained during 12 months of follow-up," Dr. Fea said. The mean IOP values at 3 hours, 1 day, 1 week, and 1, 3, 6, 9, and 12 months, respectively, were 20.1, 19.6, 18.7, 18.9, 19.2, 19.2, 19.3, and 19.5 mm Hg.

Treatment was considered a success in 24 of the 32 study eyes. In the remaining eight eyes, six eyes that had a mean IOP of 25.3 mm Hg at baseline did not respond to treatment during the first week, and the IOP decrease was not maintained at the 6-month examination in the two eyes of one patient.

When the 24 eyes were analyzed by the number that reached various levels of reduction in IOP (less than 20%, between 20% and 29%, and 30% or more), 16 experienced an IOP decrease of 20% or more (mean, 22%).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.